Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Heat Biologics Inc (HTBX)

Heat Biologics Inc (HTBX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 178,287
  • Shares Outstanding, K 25,397
  • Annual Sales, $ 2,950 K
  • Annual Income, $ -26,050 K
  • 60-Month Beta 0.31
  • Price/Sales 63.49
  • Price/Cash Flow N/A
  • Price/Book 1.41
Trade HTBX with:

Options Overview

Details
  • Implied Volatility 136.86%
  • Historical Volatility 151.08%
  • IV Percentile 79%
  • IV Rank 41.32%
  • IV High 218.07% on 06/10/21
  • IV Low 79.67% on 05/24/21
  • Put/Call Vol Ratio 0.14
  • Today's Volume 1,381
  • Volume Avg (30-Day) 1,823
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 18,842
  • Open Int (30-Day) 11,367

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.28
  • Number of Estimates 3
  • High Estimate -0.26
  • Low Estimate -0.29
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.90 +18.98%
on 05/17/21
10.85 -35.30%
on 06/10/21
+1.07 (+17.98%)
since 05/14/21
3-Month
5.68 +23.59%
on 05/13/21
10.85 -35.30%
on 06/10/21
-1.82 (-20.59%)
since 03/15/21
52-Week
4.90 +43.27%
on 06/24/20
30.10 -76.68%
on 07/21/20
+1.51 (+27.43%)
since 06/15/20

Most Recent Stories

More News
Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients at 2021 American Society of Clinical Oncology Annual Meeting

Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Dr. Roger B. Cohen, MD,...

HTBX : 7.02 (-4.75%)
Heat Biologics Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer; Selected for Presentation at 2021 American Society of Clinical Oncology Annual Meeting

Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that the latest data from HS-110,...

HTBX : 7.02 (-4.75%)
Heat Biologics Announces Multiple Presentations on PTX-35 at the Upcoming 3rd Annual Treg Directed Therapies Summit

Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that PTX-35 will be featured...

HTBX : 7.02 (-4.75%)
Heat Biologics Appoints Anthony Manning, Ph.D. as Chief Scientific Advisor

Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates...

ALRN : 1.2900 (-5.15%)
MNTA : 52.48 (-0.02%)
PTN : 0.5566 (-8.75%)
HTBX : 7.02 (-4.75%)
Heat Biologics Provides First Quarter 2021 Business Update; Reports Continued Progress on Oncology and COVID-19 Vaccine Programs

Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product...

HTBX : 7.02 (-4.75%)
Heat Biologics Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Cancer Research (AACR) Annual Meeting 2021

DURHAM, NC / ACCESSWIRE / April 12, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including...

HTBX : 7.02 (-4.75%)
Heat Biologics Provides Year-End Business Update

Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates...

HTBX : 7.02 (-4.75%)
Heat Biologics to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

DURHAM, NC / ACCESSWIRE / March 8, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including...

HTBX : 7.02 (-4.75%)
Thinking about buying stock in Ovid Therapeutics, KemPharm, Super League Gaming, Heat Biologics, or TherapeuticsMD?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OVID, KMPH, SLGG, HTBX, and TXMD.

KMPH : 15.00 (+4.17%)
OVID : 4.41 (-0.90%)
SLGG : 5.65 (-3.09%)
TXMD : 1.2600 (-2.33%)
HTBX : 7.02 (-4.75%)
Heat Biologics to Present at 2021 BIO CEO & Investor Digital Conference

DURHAM, NC / ACCESSWIRE / February 12, 2021 / Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...

HTBX : 7.02 (-4.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Heat Biologics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases. The Company's products under development include HS-110 for the treatment of non-small cell...

See More

Key Turning Points

3rd Resistance Point 7.66
2nd Resistance Point 7.51
1st Resistance Point 7.26
Last Price 7.02
1st Support Level 6.86
2nd Support Level 6.71
3rd Support Level 6.46

See More

52-Week High 30.10
Fibonacci 61.8% 20.47
Fibonacci 50% 17.50
Fibonacci 38.2% 14.53
Last Price 7.02
52-Week Low 4.90

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar